Literature DB >> 25728775

De novo nonsense mutations in KAT6A, a lysine acetyl-transferase gene, cause a syndrome including microcephaly and global developmental delay.

Valerie A Arboleda1, Hane Lee1, Naghmeh Dorrani2, Neda Zadeh3, Mary Willis4, Colleen Forsyth Macmurdo5, Melanie A Manning6, Andrea Kwan7, Louanne Hudgins5, Florian Barthelemy8, M Carrie Miceli8, Fabiola Quintero-Rivera1, Sibel Kantarci1, Samuel P Strom1, Joshua L Deignan1, Wayne W Grody9, Eric Vilain10, Stanley F Nelson11.   

Abstract

Chromatin remodeling through histone acetyltransferase (HAT) and histone deactylase (HDAC) enzymes affects fundamental cellular processes including the cell-cycle, cell differentiation, metabolism, and apoptosis. Nonsense mutations in genes that are involved in histone acetylation and deacetylation result in multiple congenital anomalies with most individuals displaying significant developmental delay, microcephaly and dysmorphism. Here, we report a syndrome caused by de novo heterozygous nonsense mutations in KAT6A (a.k.a., MOZ, MYST3) identified by clinical exome sequencing (CES) in four independent families. The same de novo nonsense mutation (c.3385C>T [p.Arg1129∗]) was observed in three individuals, and the fourth individual had a nearby de novo nonsense mutation (c.3070C>T [p.Arg1024∗]). Neither of these variants was present in 1,815 in-house exomes or in public databases. Common features among all four probands include primary microcephaly, global developmental delay including profound speech delay, and craniofacial dysmorphism, as well as more varied features such as feeding difficulties, cardiac defects, and ocular anomalies. We further demonstrate that KAT6A mutations result in dysregulation of H3K9 and H3K18 acetylation and altered P53 signaling. Through histone and non-histone acetylation, KAT6A affects multiple cellular processes and illustrates the complex role of acetylation in regulating development and disease.
Copyright © 2015 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25728775      PMCID: PMC4375619          DOI: 10.1016/j.ajhg.2015.01.017

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  46 in total

1.  Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein.

Authors:  I Kitabayashi; Y Aikawa; L A Nguyen; A Yokoyama; M Ohki
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

2.  A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia.

Authors:  M Carapeti; R C Aguiar; J M Goldman; N C Cross
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

3.  The monocytic leukemia zinc finger protein MOZ is a histone acetyltransferase.

Authors:  N Champagne; N Pelletier; X J Yang
Journal:  Oncogene       Date:  2001-01-18       Impact factor: 9.867

4.  The acid extraction of histones from calf thymus deoxyribonucleoprotein.

Authors:  K Murray
Journal:  J Mol Biol       Date:  1966-02       Impact factor: 5.469

5.  Clinical exome sequencing for genetic identification of rare Mendelian disorders.

Authors:  Hane Lee; Joshua L Deignan; Naghmeh Dorrani; Samuel P Strom; Sibel Kantarci; Fabiola Quintero-Rivera; Kingshuk Das; Traci Toy; Bret Harry; Michael Yourshaw; Michelle Fox; Brent L Fogel; Julian A Martinez-Agosto; Derek A Wong; Vivian Y Chang; Perry B Shieh; Christina G S Palmer; Katrina M Dipple; Wayne W Grody; Eric Vilain; Stanley F Nelson
Journal:  JAMA       Date:  2014-11-12       Impact factor: 56.272

6.  Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells.

Authors:  Tim Thomas; Lynn M Corcoran; Raffi Gugasyan; Mathew P Dixon; Thomas Brodnicki; Stephen L Nutt; Donald Metcalf; Anne K Voss
Journal:  Genes Dev       Date:  2006-05-01       Impact factor: 11.361

7.  Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration.

Authors:  Juan M Alarcón; Gaël Malleret; Khalid Touzani; Svetlana Vronskaya; Shunsuke Ishii; Eric R Kandel; Angel Barco
Journal:  Neuron       Date:  2004-06-24       Impact factor: 17.173

8.  The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein.

Authors:  J Borrow; V P Stanton; J M Andresen; R Becher; F G Behm; R S Chaganti; C I Civin; C Disteche; I Dubé; A M Frischauf; D Horsman; F Mitelman; S Volinia; A E Watmore; D E Housman
Journal:  Nat Genet       Date:  1996-09       Impact factor: 38.330

Review 9.  MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells.

Authors:  X-J Yang; M Ullah
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

10.  Polycomb- and REST-associated histone deacetylases are independent pathways toward a mature neuronal phenotype.

Authors:  James C McGann; Jon A Oyer; Saurabh Garg; Huilan Yao; Jun Liu; Xin Feng; Lujian Liao; John R Yates; Gail Mandel
Journal:  Elife       Date:  2014-09-24       Impact factor: 8.140

View more
  48 in total

Review 1.  The frontiers of sequencing in undiagnosed neurodevelopmental diseases.

Authors:  Hane Lee; Stanley F Nelson
Journal:  Curr Opin Genet Dev       Date:  2020-06-27       Impact factor: 5.578

Review 2.  What can Duchenne Connect teach us about treating Duchenne muscular dystrophy?

Authors:  Richard T Wang; Stanley F Nelson
Journal:  Curr Opin Neurol       Date:  2015-10       Impact factor: 5.710

Review 3.  Regulation and role of post-translational modifications of enhancer of zeste homologue 2 in cancer development.

Authors:  Haiqi Lu; Guangliang Li; Chenyi Zhou; Wei Jin; Xiaoling Qian; Zhuo Wang; Hongming Pan; Hongchuan Jin; Xian Wang
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

Review 4.  Neurodevelopmental and Psychiatric Symptoms in Patients with a Cyst Compressing the Cerebellum: an Ongoing Enigma.

Authors:  Xavier Guell; Sheeba A Anteraper; Satrajit S Ghosh; John D E Gabrieli; Jeremy D Schmahmann
Journal:  Cerebellum       Date:  2020-02       Impact factor: 3.847

5.  De Novo KAT5 Variants Cause a Syndrome with Recognizable Facial Dysmorphisms, Cerebellar Atrophy, Sleep Disturbance, and Epilepsy.

Authors:  Jonathan Humbert; Smrithi Salian; Periklis Makrythanasis; Gabrielle Lemire; Justine Rousseau; Sophie Ehresmann; Thomas Garcia; Rami Alasiri; Armand Bottani; Sylviane Hanquinet; Erin Beaver; Jennifer Heeley; Ann C M Smith; Seth I Berger; Stylianos E Antonarakis; Xiang-Jiao Yang; Jacques Côté; Philippe M Campeau
Journal:  Am J Hum Genet       Date:  2020-08-20       Impact factor: 11.025

6.  A Novel De Novo Frameshift Mutation in KAT6A Identified by Whole Exome Sequencing.

Authors:  Asem Alkhateeb; Wafa Alazaizeh
Journal:  J Pediatr Genet       Date:  2018-12-26

7.  Missense variants in the chromatin remodeler CHD1 are associated with neurodevelopmental disability.

Authors:  Genay O Pilarowski; Hilary J Vernon; Carolyn D Applegate; Leandros Boukas; Megan T Cho; Christina A Gurnett; Paul J Benke; Erin Beaver; Jennifer M Heeley; Livija Medne; Ian D Krantz; Meron Azage; Dmitriy Niyazov; Lindsay B Henderson; Ingrid M Wentzensen; Berivan Baskin; Maria J Guillen Sacoto; Gregory D Bowman; Hans T Bjornsson
Journal:  J Med Genet       Date:  2017-09-02       Impact factor: 6.318

Review 8.  Clinical exome sequencing in neurogenetic and neuropsychiatric disorders.

Authors:  Brent L Fogel; Hane Lee; Samuel P Strom; Joshua L Deignan; Stanley F Nelson
Journal:  Ann N Y Acad Sci       Date:  2015-08-06       Impact factor: 5.691

9.  BRPF1 is essential for development of fetal hematopoietic stem cells.

Authors:  Linya You; Lin Li; Jinfeng Zou; Kezhi Yan; Jad Belle; Anastasia Nijnik; Edwin Wang; Xiang-Jiao Yang
Journal:  J Clin Invest       Date:  2016-08-08       Impact factor: 14.808

Review 10.  Regulation of KAT6 Acetyltransferases and Their Roles in Cell Cycle Progression, Stem Cell Maintenance, and Human Disease.

Authors:  Fu Huang; Susan M Abmayr; Jerry L Workman
Journal:  Mol Cell Biol       Date:  2016-06-29       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.